• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cardiac myosin inhibitors: a silver lining for an old disease.

作者信息

Yadav Satyavir, Agstam Sourabh, Singh Sandeep

机构信息

Cardiology, AIIMS, New Delhi, India

Cardiology, AIIMS, New Delhi, India.

出版信息

Open Heart. 2025 Jun 10;12(1):e003358. doi: 10.1136/openhrt-2025-003358.

DOI:10.1136/openhrt-2025-003358
PMID:40500110
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12161426/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451e/12161426/152e09540965/openhrt-12-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451e/12161426/152e09540965/openhrt-12-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451e/12161426/152e09540965/openhrt-12-1-g001.jpg

相似文献

1
Cardiac myosin inhibitors: a silver lining for an old disease.心肌肌球蛋白抑制剂：一种古老疾病的一线希望。
Open Heart. 2025 Jun 10;12(1):e003358. doi: 10.1136/openhrt-2025-003358.
2
Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events.肥厚型心肌病患者的基因型阳性状态与更高的心力衰竭事件发生率相关。
Circ Cardiovasc Genet. 2014 Aug;7(4):416-22. doi: 10.1161/CIRCGENETICS.113.000331. Epub 2014 Jun 8.
3
Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal.梗阻性肥厚型心肌病治疗后有利的心脏重塑：当前评估
Future Cardiol. 2025 Jun;21(7):527-537. doi: 10.1080/14796678.2025.2501466. Epub 2025 Jun 3.
4
Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly.老年人肥厚型心肌病中的肌节蛋白基因突变
Circulation. 2002 Jan 29;105(4):446-51. doi: 10.1161/hc0402.102990.
5
Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics.新兴疗法时代肥厚型心肌病的基线和纵向影像学评估。
Curr Cardiol Rep. 2023 Jun;25(6):583-595. doi: 10.1007/s11886-023-01883-w. Epub 2023 Apr 27.
6
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.心肌肌球蛋白结合蛋白C基因的突变与迟发性家族性肥厚型心肌病
N Engl J Med. 1998 Apr 30;338(18):1248-57. doi: 10.1056/NEJM199804303381802.
7
Molecular basis of hypertrophic and dilated cardiomyopathy.肥厚型和扩张型心肌病的分子基础。
Tex Heart Inst J. 1994;21(1):6-15.
8
Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials.心肌肌球蛋白抑制剂mavacamten和aficamten在肥厚型心肌病中的疗效：一项随机对照试验的系统评价和荟萃分析
Open Heart. 2025 Feb 23;12(1):e003215. doi: 10.1136/openhrt-2025-003215.
9
Heterogeneous Dysregulation of Myosin Super-Relaxation and Energetics in Hypertrophic Cardiomyopathy.肥厚型心肌病中肌球蛋白超松弛和能量学的异质性失调
Circ Heart Fail. 2025 May 20:e012614. doi: 10.1161/CIRCHEARTFAILURE.124.012614.
10
Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.辛伐他汀可使人类肥厚型心肌病转基因兔模型的心肌肥厚和纤维化消退，并改善心脏功能。
Circulation. 2001 Jul 17;104(3):317-24. doi: 10.1161/hc2801.094031.

本文引用的文献

1
Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.三项服务的故事：英国早期使用马伐卡坦治疗左心室流出道梗阻性肥厚型心肌病的经验
Open Heart. 2025 Apr 17;12(1):e003218. doi: 10.1136/openhrt-2025-003218.
2
Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy.麦卡姆坦维持剂量的确定：肥厚型心肌病个体化治疗的见解
Open Heart. 2025 Mar 28;12(1):e003192. doi: 10.1136/openhrt-2025-003192.
3
Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials.
心肌肌球蛋白抑制剂mavacamten和aficamten在肥厚型心肌病中的疗效：一项随机对照试验的系统评价和荟萃分析
Open Heart. 2025 Feb 23;12(1):e003215. doi: 10.1136/openhrt-2025-003215.
4
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM.玛伐卡坦治疗有症状的非梗阻性肥厚型心肌病：ODYSSEY-HCM研究的设计、原理及基线特征
JACC Heart Fail. 2025 Feb;13(2):358-370. doi: 10.1016/j.jchf.2024.11.013.
5
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.2024 AHA/ACC/AMSSM/HRS/PACES/SCMR 肥厚型心肌病管理指南：美国心脏协会/美国心脏病学会联合临床实践指南委员会的报告。
Circulation. 2024 Jun 4;149(23):e1239-e1311. doi: 10.1161/CIR.0000000000001250. Epub 2024 May 8.
6
Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.马卡丹特治疗有症状梗阻性肥厚型心肌病的长期安全性和疗效：PIONEER-OLE 研究的中期结果。
J Am Heart Assoc. 2024 Apr 16;13(8):e030607. doi: 10.1161/JAHA.123.030607. Epub 2024 Apr 9.
7
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.马卡丹特治疗有症状梗阻性肥厚型心肌病：来自 MAVA-LTE 研究的中期结果，EXPLORER-LTE 队列。
JACC Heart Fail. 2024 Jan;12(1):164-177. doi: 10.1016/j.jchf.2023.09.028.
8
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.肥厚型心肌病患者行间隔心肌切除术的治疗：VALOR-HCM 随机临床试验第 56 周的结果。
JAMA Cardiol. 2023 Oct 1;8(10):968-977. doi: 10.1001/jamacardio.2023.3342.
9
2023 ESC Guidelines for the management of cardiomyopathies.2023年欧洲心脏病学会心肌病管理指南。
Eur Heart J. 2023 Oct 1;44(37):3503-3626. doi: 10.1093/eurheartj/ehad194.
10
Prognosis of patients with hypertrophic cardiomyopathy and low-normal left ventricular ejection fraction.肥厚型心肌病且左心室射血分数略低于正常水平患者的预后
Heart. 2023 Apr 25;109(10):771-778. doi: 10.1136/heartjnl-2022-321853.